{"id":"carbetocin-short-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Flushing"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carbetocin mimics the natural hormone oxytocin by activating oxytocin receptors on uterine smooth muscle, triggering sustained contractions that compress bleeding vessels and reduce postpartum hemorrhage. It has a longer duration of action and more stable pharmacokinetics compared to oxytocin, making it suitable for short infusion administration during and after cesarean delivery or vaginal delivery.","oneSentence":"Carbetocin is a synthetic oxytocin analogue that binds to oxytocin receptors to stimulate uterine contractions and promote hemostasis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:46.949Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention and treatment of postpartum hemorrhage during cesarean delivery"},{"name":"Prevention and treatment of postpartum hemorrhage during vaginal delivery"}]},"trialDetails":[{"nctId":"NCT03708497","phase":"NA","title":"Carbetocin Versus Oral Tranexamic Acid Plus, Buccal Misoprostol on Blood Loss After Vaginal Delivery","status":"COMPLETED","sponsor":"Aswan University Hospital","startDate":"2018-12-01","conditions":"Postpartum Hemorrhage","enrollment":360},{"nctId":"NCT02221531","phase":"PHASE4","title":"Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-08","conditions":"Complications; Cesarean Section, Anesthesia; Reaction","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Carbetocin Short-infusion","genericName":"Carbetocin Short-infusion","companyName":"University Hospital, Basel, Switzerland","companyId":"university-hospital-basel-switzerland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbetocin is a synthetic oxytocin analogue that binds to oxytocin receptors to stimulate uterine contractions and promote hemostasis. Used for Prevention and treatment of postpartum hemorrhage during cesarean delivery, Prevention and treatment of postpartum hemorrhage during vaginal delivery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}